£810 / $1295 / €985
While the Netherlands is a low-risk market from the point of view of multinational drugmakers, the country's modest per capita expenditure on pharmaceuticals relative to other Western European countries is an issue. Another challenge facing drugmakers is cost-containment, which will only intensify as the Netherlands enters a period of slower economic growth. In fact, as we warned , the Dutch authorities recently introduced a new scheme - reimbursement for medicines that prove therapeutically ineffective will be reclaimed from the manufacturer - to reduce public healthcare costs. BMI notes that the 'no cure, no pay' scheme implemented by the Dutch government is not a new concept , with t he US government and a number of Western European governments already having made risk - sharing or money-back guarantee agreements with drug companies. However, these agreements focused on particular medicines, unlike the much harsher 'blanket' stance of the Dutch health ministry.
Headline Expenditure Projections
Pharmaceuticals : EUR6.70bn (US$9.31bn) in 2011 to EUR6.51bn (US$8.27bn) in 2012; -2.8% in local currency terms and -11.2% in US dollar terms. Forecast unchanged from Q4 12.
Healthcare : EUR62.94bn (US$87.49bn) in 2011 to EUR64.43bn (US$81.83bn) in 2012; +2.4% in local currency terms and -6.5% in US dollar terms. Forecast unchanged from Q4 12.
Medical d evices: EUR11.41bn (US$15.86bn) in 2011 to EUR11.72bn (US$14.89bn) in 2012; +2.8% in local currency terms and -6.1% in US dollar terms. Forecast unchanged from Q4 12.
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.